Shares of Switzerland’s Actelion spiked 15% Monday morning after the biotech reported that its next-gen oral pulmonary arterial hypertension drug selexipag proved a success in Phase III, setting up a showdown with regulators for a drug that’s widely billed as a likely blockbuster.

…read more

Source: Actelion racing to regulators after potential blockbuster PAH drug aces PhIII


0 No comments